Diamedica Therapeutics INC

DiaMedica Therapeutics Inc. announced the results of its 2026 Annual General Meeting, with shareholders re-electing all seven director nominees and approving the company's independent auditor, executive compensation, and an amendment to its incentive plan.

DiaMedica Therapeutics reported Q1 2026 financial results, highlighting progress in its preeclampsia and acute ischemic stroke trials, with cash reserves projected through 2027.

DiaMedica Therapeutics Inc. sold 1,501,000 common shares to a healthcare institution fund, generating $12.2 million in gross proceeds.

DiaMedica Therapeutics announced an update on its DM199 preeclampsia program, revealing the FDA requested an additional non-clinical study, while an ongoing Phase 2 trial shows encouraging interim data.

DiaMedica Therapeutics announced its third quarter 2025 financial results and provided updates on its preeclampsia and acute ischemic stroke clinical programs, including progress in patient enrollment and an extended cash runway.

DiaMedica Therapeutics Inc. has established an At-The-Market equity offering program to sell up to $100 million in common shares through TD Securities (USA) LLC.

DiaMedica Therapeutics reports on progress in its DM199 clinical trials for preeclampsia and acute ischemic stroke, while continuing to incur operating losses and seeking additional financing.

DiaMedica Therapeutics appoints Dr. Julie Krop as Chief Medical Officer, reports increased net loss and cash burn, but positive interim PE trial data and successful capital raise.

DiaMedica Therapeutics reports increased losses in Q2 2025, positive interim data for its preeclampsia trial, but faces continued enrollment delays in its acute ischemic stroke study.

DiaMedica Therapeutics reports a net loss of $7.7 million for Q1 2025 and provides updates on its preeclampsia and acute ischemic stroke clinical programs.

DiaMedica Therapeutics reported its Q3 2024 financial results and provided updates on its ongoing clinical trials for DM199, including expansion into preeclampsia.

DiaMedica Therapeutics reported its Q2 2024 financial results, highlighting progress in its ReMEDy2 trial for acute ischemic stroke and expansion into preeclampsia treatment.

DiaMedica Therapeutics' 2025 annual report details progress in DM199 clinical trials for preeclampsia and stroke, alongside financial losses and enrollment challenges.

DiaMedica Therapeutics focuses on advancing its DM199 clinical programs for acute ischemic stroke and preeclampsia, with key milestones expected in 2025.

DiaMedica Therapeutics Inc. outlines the details of its registered voting common shares, including voting, dividend, and liquidation rights, as well as anti-takeover provisions.

Director Randall Michael Giuffre was granted 40,412 stock options in DiaMedica Therapeutics Inc. on June 1, 2026.

Director Richard Kuntz was granted 40,412 stock options in DiaMedica Therapeutics Inc. as part of his compensation.

DiaMedica Therapeutics Inc. Director Daniel J. O'Connor was granted 40,412 stock options with an exercise price of $5.84, vesting quarterly.

DiaMedica Therapeutics Inc. Director Tanya Lewis was granted 40,412 stock options with an exercise price of $5.84, vesting quarterly.

DiaMedica Therapeutics Inc. director Charles Pauling Semba was granted 40,412 stock options with an exercise price of $5.84, vesting quarterly.

Director James T. Parsons of DiaMedica Therapeutics Inc. has filed a Form 4, reporting a transaction related to stock options.

DiaMedica Therapeutics Inc. announced its 2026 Annual General Meeting to vote on director elections, auditor ratification, executive compensation, and a significant increase in its equity incentive plan shares.

DiaMedica Therapeutics Inc. has filed a definitive proxy statement with the SEC.

DiaMedica Therapeutics will hold its 2025 Annual General Meeting on May 15, 2025, to vote on the election of directors, appointment of an independent accounting firm, and executive compensation.

DiaMedica Therapeutics Inc. has filed a definitive proxy statement with the SEC.

DiaMedica Therapeutics is asking shareholders to approve an amendment to its 2019 Omnibus Incentive Plan and provide advisory votes on executive compensation at the upcoming Annual General Meeting.

Dialectic Life Sciences SPV LLC and related entities filed an amended Schedule 13G, reporting John Fichthorn's beneficial ownership of 0.3% in DiaMedica Therapeutics Inc.

Trill AB and Jan Stahlberg have reported a 16.9% beneficial ownership stake in DiaMedica Therapeutics Inc., holding 8,825,742 common shares.

Richard Jacinto II has increased his beneficial ownership in DiaMedica Therapeutics Inc. to 9.6% of outstanding Voting Common Shares.

Leon G. Cooperman and his foundation have reported a 6.3% beneficial ownership stake in DiaMedica Therapeutics Inc., totaling 3,269,761 common shares.

Trill AB and Jan Stahlberg have reported a combined beneficial ownership of 15.02% of DiaMedica Therapeutics Inc. common shares.

Veteran investor Leon Cooperman has revealed a 6% passive ownership stake in DiaMedica Therapeutics Inc., holding over 3.1 million common shares.